文章：

胰腺癌的免疫治疗——推动临床进步的科学

Immunotherapy for pancreatic cancer — science driving clinical progress

原文发布日期：2005-05-20

DOI: 10.1038/nrc1630

类型: Review Article

开放获取: 否

要点：

1. Pancreatic cancer represents a significant challenge, as the tumour cells are naturally resistant to current chemotherapy and radiation therapy.
2. Mechanisms of immune escape both at the local and systemic level are recognized. Such mechanisms will probably need to be circumvented to fully develop an effective pancreatic cancer vaccine.
3. So far, monoclonal antibodies to vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) have been tested in combination with chemotherapy in patients with advanced pancreatic cancer.
4. Several pancreatic vaccine approaches have been tested including peptide-based and gene-modified whole-cell vaccine approaches, both in patients with resected pancreatic cancer who are at risk for recurrence and in patients with advanced disease.
5. New immunotherapy targets have been identified and the discovery of a relevant pancreatic cancer animal model should lead to more efficient and rapid testing and development of vaccine strategies.
6. It is clear that the most effective strategy will require a combined approach incorporating the best targeted interventions taken from each respective modality.

要点翻译：

1. 胰腺癌构成了一个重大挑战，因为肿瘤细胞天然对当前的化疗和放射治疗具有抵抗力。
2. 研究已确认其在局部和全身层面的免疫逃逸机制。要成功开发有效的胰腺癌疫苗，很可能需要规避这些机制。
3. 迄今为止，已在晚期胰腺癌患者中测试了血管内皮生长因子（VEGF）和表皮生长因子受体（EGFR）的单克隆抗体与化疗联合疗法。
4. 多种胰腺癌疫苗方法已进行临床试验，包括基于肽的疫苗和基因修饰的全细胞疫苗，这些试验既针对有复发风险的已切除胰腺癌患者，也针对晚期疾病患者。
5. 新的免疫治疗靶点已被识别，且相关胰腺癌动物模型的发现有望推动疫苗策略更高效、快速地测试与发展。
6. 显然，最有效的策略需要采用综合方法，整合从各种治疗模式中筛选出的最佳靶向干预措施。

英文摘要：

The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.

摘要翻译： 

在免疫调节关键信号通路的识别，以及小鼠模型中早期胰腺肿瘤发展的研究基础上，胰腺癌的治疗与预防迎来了新的契机。胰腺癌的免疫疗法正处于关键十字路口，针对胰腺癌相关抗原及调控信号分子设计的药物已陆续进入临床试验阶段。

原文链接：

Immunotherapy for pancreatic cancer — science driving clinical progress